Advisory Committees Turn Down Opana IR Pediatric Labeling By Sam | September 26, 2019 Two FDA advisory committees voted 16-8 on Thursday against recommending pediatric labeling for Endo Pharma’s Opana IR (immediate-release oxymorphone). Source: Drug Industry Daily Posted in Drug Industry Daily